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WE investigated the effect of transforming factor
factor-l (TGF-D on thromboxane B2 (TXB2) and
prostaglandin E2 (PGE2) production in in vitro
silica dust-exposed rat alveolar macrophages
(AM). In the presence of 5g of anti-TGF-l anti-
bodies, TXB2 production decreased, but PGE2 pro-
duction increased. Addition of 2 ng of TGF- to
the culture medium potentiated TXB2 production,
but PGE2 production apparently did not change.
At 50ng of TGF-I, TXB2 production decreased,
and PGE2 production varied. Our data suggest
that in rat AM: (1) both endogenous and exogen-
ous TGF-x regulate TXB2 production; and (2) in
the absence of endogenous TGF-I the liberation
of PGE2 increases; however, exogenous TGF-
does not have a regulatory effect on PGE2.
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Introduction
Chronic airway inflammation and lung fibrosis
are common features of prolonged exposure to
mineral particles of silica in humans and in
rodents. Alveolar macrophages (AM) have an
essential role in lung clearance and defence
mechanisms against inhaled particles.
2 They fulfil
these functions via inflammatory mediators pro-
duced upon macrophage activation. Among the
many mediators are arachidonic acid metabolites
such as thromboxane A2 (TXA2) and pros-
taglandin E2 (PGE2). Thromboxane A2 (of which
TXB2 is the stable metabolite) is a very potent
platelet aggregating factor and pulmonary vaso-
constrictor. A recent study of the regulatory
effect of TXB2 on the proliferation of vascular
smooth muscle cells from rats demonstrated a
rapid build-up of cytoskeletal protein in these
cells in hypertension, suggesting that TXB2 may
play a role in the remodelling of the vascular wall
in hypertension.’4
Prostaglandin E2 is one of the key inflamma-
tory mediators with multiple functions. In the
lung, it induces bronchodilation and causes an
increase in epithelial cell chloride secretion.5
PGE2 induces vasodilatation in unventilated foetal
lung.
6
Another mediator that is produced by alveolar
macrophages is transforming growth factor-131
(TGF-131). TGF-131 is a multifunctional peptide.
TGF-I can influence cell proliferation or differ-
entiation and other functions in various types of
cells, some of which are related to inflammation
and tissue fibrosis. For example, TGF-I3 increa-
ses the rate of fibronectin gene transcription,
7
can down-regulate interleukin-l[3 receptors,
8 and
inhibits interleukin-6 release from fibroblasts.9
The most profound effect of TGF-[3 is its ability
to enhance the formation of extracellular matrix.
TGF-131 promotes the formation of collagen and
fibronectin in fibroblasts of human, rat and
mouse origin. From in vivo studies, it has been
shown that TGF-I3 can stimulate the formation
of the typical granulation tissue found in tissue
repair.
Although pulmonary macrophage-derived med-
iators have a pivotal role in lung inflammation
and fibrosis, the interrelationship between these
mediators is just beginning to be understood. We
have shown the very early release (15 min) of
TGF-131 from silica dust-exposed rat alveolar mac-
rophages.
1 The amount of TGF-131 released at
this time was the greatest over 24h kinetic
studies, and preceded the production of TXB2
and PGE2. To further unravel the interrelation-
ship between eicosanoids and TGF-131 produced
by alveolar macrophage, the modification of
TXB2 and PGE2 production by TGF-131 in in
vitro silica-exposed rat alveolar macrophages was
investigated. We observed decreased production
of TXB2 in the presence of anti-TGF-131 anti-
bodies, or high concentration (50 ng) of TGF-131.
TXB2 production increased in the presence of a
low concentration of TGF-J31 (2ng) in the
culture medium. PGE2 production increased in
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the presence of anti-TGF-13 antibodies. Exogen- bated at 37C for 24h. After incubation the
ous TGF-31 at low or high concentration did not medium containing arachidonic acid was
have any effect on PGE2 production in rat alveo- removed and fresh culture medium was placed in
lar macrophages, the wells. Macrophages were activated with a
microcrystalline form of silica dust (Min-U Sil, 2-
Materials and Methods 71.tm diameter, provided by Dr Peter Bolsitis,
MIT) at a final concentration of 2001.tg/ml, at
Materials.. Hanks’ solution and Dulbecco’s phos- 37C for 24h, in the absence or presence of
phate buffered saline (DPBS), and HEPES (4-(2- anti-TGF-[31 antibodies, or TGF-3. Nonspecific
hydroxyethyl)-l-piperazine ethanesulfonic acid) antibody as an isotype-matched control for anti-
buffer were prepared in our laboratory. Six-well TGF-[3 antibody was tested. Media were collected
tissue culture plates were obtained from Falcon into silianized tubes for the determination of
Laboratory Products (Beckton and Dickinson eicosanoids.
Labware, Lincoln Park, NJ). DMSO (dimethylsulf-
oxide) was obtained from Calbiochem (San Radioimmunoassay for TXB2 and PGE2: Fol-
Diego, CA). Allopurinol, oxypurinol, allopurinol lowing incubation, the culture medium was
riboside, Penn/Strep, M199 medium (without removed and acidified to pH 3.0 with 1 N HC1.
phenol red), and human serum albumin were all Eicosanoids were extracted twice with 2 ml ethyl
obtained from Sigma (St. Louis, MO). Human acetate/cyclohexane (1:1). The extracts were
recombinant and polyclonal anti-TGF-13 antibody stored at -20C until analysis of eicosanoids by
were obtained from R&D Systems (Minneapolis, specific radioimmunoassay, as described pre-
MN). RIA reagents for TXB2 and PGE2 assay viously.
12 The antibodies utilized in the assay of
were purchased from Advanced Magnetics, Inc. TXB2 or PGE2 showed less than 1% cross-reac-
(Boston, MA). tivity with other eicosanoids.
Isolation and culture of rat alveolar macro- Cell viability test.. The lactate dehydrogenase
phages.. Sprague-Dawley rats weighing approxi- (LDH) activity in rat culture conditions was mea-
mately 225 g were lavaged ex vivo. Rats were sured using a Sigma kit for LDH. There was no
given an intramuscular injection of sodium pen- detectable LDH enzyme activity in the culture
tabarbital (10mg) and the rib cage was opened medium from rat alveolar macrophages.
to expose the lungs. An incision halfway through
the trachea was made and the lavage tube of the Data analysis.. Results are presented as means
trachea cannula was inserted into the incision. _--t-S.E. of a number of independent experiments.
The lungs were washed five times each with
10ml of lavage fluid (phosphate-buffered saline
containing 0.1% EDTA, at 37C). The collected Results lavage fluid was filtered through sterile Nitex
gauze and centrifuged at 250 x g for 10 min. The effect of TGF-fll on 2XB production in rat
The supernatant was discarded, and the cells alveolar macrophages: Table 1 shows the effect
resuspended in M199, 10mM HEPES 0.3% of anti-TGF-[3 antibodies, or low or high con-
human serum albumin, 100U/ml penicillin and centrations of TGF-I3, on TXB2 production in
1001.tg/ml streptomycin (culture medium). Cells silica-exposed rat alveolar macrophages. In the
from all rats were pooled and centrifuged again presence of 5 l.tg of anti-TGF-[3 antibodies in the
at 250 x g for 10 min. Cells were enumerated in culture medium, during the process of macro-
a haemocytometer. Viability was determined by phage activation with silica, the production of
the exclusion of trypan blue and cells were TXB2 was inhibited. The TGF-[3, at 2ng con-
plated at 1 x 106/ml of culture medium in 6-well centration in the culture medium, potentiated
culture plates. The cells were preincubated for TXB2 production. At 50ng of TGF-[3 in the
l h at 37C in a humidified atmosphere at 5% culture medium, the production of TXB2 was
CO in air. The nonadherent cells were removed inhibited.
by aspiration. Fresh culture medium (37C) was
placed in the wells and unlabelled arachidonic The effect of TGF-fll on PGEe production in rat
acid was added at a final concentration of 3 l.tM. alveolar macrophages Table 2 shows the effect
This incubation with arachidonic acid was con- of anti-TGF-[3 antibodies, or low or high con-
ducted in order to replenish endogenous arachi- centrations of TGF-13, on PGE2 production in
donic acid utilized during the exaggerated silica-exposed rat alveolar macrophage. In the
eicosanoid production which occurs during cell presence of 5 l.tg of anti-TGF-3 antibodies in the
isolation and attachment. The cells were incu- culture medium, the production of PGE2 was
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Table 1. The effect of TGF-I on TXB2 production by rat alveolar macrophages exposed to silica dust
Treatment Experiment Experiment 2 Experiment 3
TXB2 (pg/ml) % Control TXB2 (pg/ml) % Control TXB2 (pg/ml) % Control
Control 62 4- 2 179 4- 5 79 4- 3
Silica 132 _+ 2 213 369 _+ 2 206 172 4- 9 218
Silica + 51g anti-TGF-Il 60 4- 5 100 313 4- 2 175 103 4- 7 130
Silica + 2ng TGF-131 ND ND 491 +_ 3 274 219 4- 2 277
Silica + 50ng TGF- 47 4- 5 76 69 4- 0 39 158 -I- 3 200
Alveolar macrophages at x 106 cells were activated with 200 Ig of silica dust in the absence or presence of antI-TGF-l antibodies, or TGF-I added at the
time of cell activation, and Incubated at 37C for 24 h. TXB2 was assayed by the RIA as descnbed in Methods. n 2 in each expenmental group. ND not done.
Table 2. The effect of TGF-I on PGE2 production by rat alveolar macrophages exposed to silica dust
Treatment Experiment Experiment 2 Experiment 3
PGE2 (pg/ml) % Control PGE2 (pg/ml) % Control PGE2 (pg/ml) % Control
Control 445 4- 6 207 4- 9 411 4- 10
Silica 939 4- 3 211 241 4- 10 116 438 4- 10 107
Silica + 51g anti-TGF-Il 1137 4- 75 256 330 -t- 9 159 783 4- 20 191
Silica + 2ng TGF-I ND ND 253 4- 3 122 457 4- 2 111
Silica + 50ng TGF-#I 840 4- 91 189 227 4- 7 110 504 4- 20 123
Alveolar macrophages at x 10 cells were activated with 200 ig of sihca dust in the absence or presence of anti-TGF-Il antibodies, or TGF-II added at the
time of cell activation, and ncubated at 37C for 24 PGE2 was assayed by the RIA as described in Methods. n 2 in each expenmental group. ND not done.
potentiated. The addition of 2ng of TGF-]31 to
the culture medium had no apparent effect on
PGE2 production in either of two experiments
performed. At 50ng of TGF-[3, the production
of PGE2 varied.
Discussion
This study was designed to evaluate the regula-
tion of TXB2 and PGE2 production by TGF-]3 in
alveolar macrophages. The reason for these
studies was to supplement the limited informa-
tion in the literature on the interrelationship
between the inflammatory mediators released by
a specific inflammatory cell. TXB2, PGE2 and
TGF-3 are the principal inflammatory mediators
released by alveolar macrophages during the
lung’s defence process against pathogens or
foreign matter. We have demonstrated in earlier
studies that these three mediators are released
from rat alveolar macrophages upon exposure to
silica dust. In those studies we observed a strik-
ing difference between the kinetics of release of
TGF-3 (maximum release at 15 min post-silica
dust) and TXB2 (plateau release at 6 h post-silica
dust), or PGE2 release (plateau release at 6h
post-silica dust). Because it is thought that TGF-
1 has a central regulatory role in vascular phy-
siology and pathology, we formulated a hypoth-
esis that perhaps TGF- has an impact on the
production of either TXB or PGE2, or both, by
alveolar macrophage upon silica dust-exposure.
We observed a positive effect of TGF-[I on
TXB2 production in rat alveolar macrophages
which had been exposed to silica dust. In the
absence of TGF-[ (plus anti-TGF-l antibodies),
the quantity of TXB2 released from rat alveolar
macrophages to the culture medium in response
to silica exposure was significantly smaller when
compared to the response with silica alcne. Exo-
genous TGF-I, at low concentration, poten-
tiated the action of silica dust, and the amount of
TXB2 produced by rat alveolar macrophages was
significantly greater than the amount of TXB2
released by alveolar macrophages activated by
silica alone. High concentration of TGF-3,
however, inhibited TXB2 production in rat alveo-
lar macrophages; in response to silica, the
amount of TXB2 released was smaller than the
amount of TXB1 produced in rat alveolar macro-
phages activated with silica alone, or in the
absence of TGF-3 (in the presence of anti-TGF-
[1 antibodies). This observation suggests that
upon exposure to silica dust a homeostatic auto-
crine loop for TGF-13, that regulates the produc-
tion of TXB2, appears to function in rat alveolar
macrophages. Our data also suggest the role for
concentration of TGF-[ in the regulation of
TXB2 production; depending on the concentra-
tion, this growth factor appears to be either sti-
mulatory or inhibitory to rat alveolar
macrophage, and to TXB2 production.
At the same time, however, the effect of TGF-
[3 on the generation of another eicosanoid,
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namely PGE2, in silica-exposed rat alveolar mac-
rophages appeared to be very different to that
observed for TXB2. In the absence of TGF-131
(plus anti-TGF-131 antibodies), the amount of
PGE2 produced in silica-exposed alveolar macro-
phages was greater than when compared to silica
alone. When anti-TGF-13 antibodies were present
in the culture medium during the exposure of
macrophages to silica, we observed that (1)
these macrophages liberated greater amount of
PGE2 compared to silica alone; and (2) there
was a stimulation of PGE2 production by alveolar
macrophages which did not produce PGE2 after
exposure to silica. Furthermore, the presence of
exogenous TGF-]3, at low or high concentra-
tions, had either no apparent effect, or a variable
effect, respectively, on PGE2 production in silica-
exposed rat alveolar macrophages when com-
pared to silica alone. Our data suggest, therefore,
a possible distinct biological role for endogen-
ous, but not exogenous TGF-131 to down-regulate
PGE2 production in rat alveolar macrophages
after exposure to silica.
Data presented in this manuscript provide evi-
dence of the regulatory role of TGF-[31 in the lib-
eration of inflammatory eicosanoids, TXB2 and
PGE2, in rat alveolar macrophages, when the
cells are exposed to silica dust. In support of our
observation are the reports of Datta et aL, where
the authors demonstrate that TGF-[31 inhibits
lipoxygenase and epoxygenase eicosanoid pro-
duction by osteosarcoma cells,1 or eicosanoid
metabolism in osteogenic osteosarcoma cells.14
The regulation of eicosanoid liberation by TGF-
[31, or the regulation of TNF<z production by
TGF-[3113 suggests that the mechanism of action
of TGF-[3 on tissues may not necessarily be
direct, but rather it requires actions of other
mediators. The interrelationship between TGF-[3
itself and all the inflammatory mediators directed
by TGF-131 in inflammation appears to be very
intriguing..
In summary, our data suggest that in silica-
exposed alveolar macrophages, both endogenous
and exogenous TGF-[3 regulate TXB2 produc-
tion. Our data suggest that endogenous, but not
exogenous TGF-[I has a regulatory role in PGE2
production. Because both TXB2 and PGE2 were
measured in the same samples, and because
there is a consistent increase in silica-stimulated
PGE2 synthesis in the presence of anti-TGF-/31
antibodies in the absence of an effect of authen-
tic TGF-I, it appears that in silica-exposed
alveolar macrophages the regulatory effects of
TGF-131 are different between the different com-
ponents of the arachidonic acid pathway.
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